Status:
UNKNOWN
Exendin PET/CT for Imaging of Paragangliomas
Lead Sponsor:
Radboud University Medical Center
Conditions:
Paraganglioma
Eligibility:
All Genders
18+ years
Brief Summary
Functional imaging of paragangliomas (PGLs) is not unequivocal. Existing functional imaging modalities show good but variable results in PGLs, warranting the search for additional molecular imaging ta...
Detailed Description
Rationale: Functional imaging of paragangliomas (PGLs) is not unequivocal. Existing functional imaging modalities show good but variable results in PGLs, warranting the search for additional molecula...
Eligibility Criteria
Inclusion
- Proven sympathetic PGL with a single tumor detected using standard diagnostic imaging
- No evidence of metastatic disease
- CT, SSTR PET/CT and 18F-FDG PET/CT performed (golden standard diagnostic imaging)
- Scheduled for surgery
- Able to sign informed consent
Exclusion
- Breast feeding
- Pregnancy or the wish to become pregnant within 1 month
- Calculated creatinine clearance below 40ml/min
- Evidence of other malignancy than PGL in conventional imaging (suspicious liver, bone and lung lesions)
- Age \< 18 years
- Not able to sign informed consent
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT05418907
Start Date
June 1 2022
End Date
December 1 2024
Last Update
December 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud University Medical Center
Nijmegen, Netherlands, 6500 HB